Research Article
Simple and Objective Prediction of Survival in Patients with Lung Cancer: Staging the Host Systemic Inflammatory Response
Table 3
The relationship between the mGPS and clinicopathological characteristics in patients with lung cancer.
| Demographic | mGPS | value (chi-square test) | 0 | 1 | 2 |
| Age | | | | | <60/60–69/70–79/≥80 years | 33/71/89/28 | 44/87/119/54 | 34/57/91/49 | 0.064 | Sex | | | | | Male/female | 115/108 | 174/130 | 133/98 | 0.201 | Centre | | | | | Aber/Fife/Stob/Inver | 98/10/77/38 | 146/25/66/67 | 43/16/126/46 | <0.001 | Deprivation | | | | | Most-least (quintile) | 68/24/71/39/21 | 75/47/75/77/30 | 111/21/70/20/9 | <0.001 | Smoke (pack years) | | | | | NS/<20/20–60/>60 | 21/24/126/37 | 11/33/177/69 | 13/21/128/57 | 0.014 | Performance status | | | | | 0/1/2/3/4 | 42/96/60/22/3 | 26/130/105/40/3 | 5/51/88/66/21 | <0.001 | Weight loss (%) | | | | | 0/<5/5–10/>10 | 147/24/12/38 | 146/36/13/109 | 79/45/33/73 | <0.001 | FEV1 (%) | | | | | <80/61–80/40–60/<40 | 138/31/45/7 | 181/48/53/22 | 130/33/47/17 | 0.126 | Local symptoms | | | | | No/yes | 36/127 | 18/222 | 29/137 | 0.246 | Tumour stage of NSCLC | | | | | I/II/IIIa/IIIb/IV | 32/11/7/38/38 | 15/19/20/56/84 | 7/5/12/36/79 | <0.001 | Tumour stage of SCLC | | | | | Limited/extensive | 13/21 | 10/32 | 8/18 | 0.471 | Treatment | | | | | Radical treatment | | | | | Surgery/RT/no active | 26/9/38 | 17/15/43 | 4/2/18 | <0.001 | Palliative treatment | | | | | Chemo/RT/No active | 63/27/49 | 107/58/55 | 50/49/75 | <0.001 | Survival | | | | | Alive/dead | 34/181 | 16/274 | 8/211 | 0.003 | 12-month survival % (SE) | 46 (4) | 16 (2) | 14 (3) | <0.001 |
|
|